



Increased intestinal phosphate absorption, an often-overlooked effect of vitamin D

R. Todd Alexander^{1,2,3}

¹Department of Physiology & ²Pediatrics, University of Alberta, Edmonton, T6G 1C9, Canada

³Membrane Protein Disease Research Group, University of Alberta, Edmonton, T6G 1C9Canada

Correspondence to:

R. Todd Alexander MD PhD

University of Alberta, Department of Pediatrics

4-585 Edmonton Clinic Health Academy

Edmonton, Alberta

Canada T6G 1C9

Email todd2@ualberta.ca

This is an Accepted Article that has been peer-reviewed and approved for publication in The Journal of Physiology, but has yet to undergo copy-editing and proof correction. Please cite this article as an 'Accepted Article'; [doi: 10.1113/JP281095](https://doi.org/10.1113/JP281095).

This article is protected by copyright. All rights reserved.

The oldest known and most important function of the active form of vitamin D, calcitriol, is to increase intestinal calcium absorption, and thus serum calcium concentration. The mechanism of action whereby calcitriol enhances intestinal calcium absorption is through increasing active transcellular and likely also passive paracellular calcium absorption (reviewed in (1)). The former effect is primarily mediated by increasing transcription of the apical calcium channel *Trpv6*, which enhances intestinal epithelial calcium entry and thus calbindin- D_{9k} expression. Calcitriol likely enhances paracellular calcium absorption by increasing the transcription of *claudin-2* and *claudin-12*, which contribute intestinal paracellular calcium pores. However, when luminal calcium levels are lower than plasma, having more intestinal calcium permeability may be counterproductive, and enhance calcium secretion and thus loss in feces (2). Clearly there are further questions with respect to how intestinal calcium absorption is increased in response to calcitriol.

The second major effect of calcitriol on intestinal mineral transport is to increase phosphate absorption. However, much less is known about how calcitriol mediates this. Increased sodium phosphate cotransporter 2b (*NaPi2b*, also known as *NaPi-IIb*, *NPTIIb*, and *NPT2b*) protein expression has been implicated, but if other apical phosphate transporters contribute, and if paracellular phosphate absorption is enhanced by calcitriol is unknown. Paracellular phosphate absorption appears, like calcium, to be the predominant pathway by which these minerals are absorbed from the gut (3). Yet the molecular details of the paracellular pathway are completely unknown. Moreover, plasma phosphate levels, which are in part regulated by intestinal absorption, associate with all-cause mortality, even in the “normal” range, making this area of enquiry all the more important.

To delineate the mechanism whereby calcitriol increases intestinal phosphate absorption Hernando et al administered calcitriol to wild-type and *Slc34a2* knockout (KO) mice (N.B. *Slc34a2* encodes the sodium-phosphate cotransporter, *NaPi2b*) and examined intestinal phosphate absorption (4). They found no effect of calcitriol administration on phosphate absorption in the

ileum. However, Ussing chamber studies performed on the jejunum *ex vivo* demonstrated increased radioactive phosphate flux in wild-type, but not *Slc34a2* KO mice, in the presence of low apical phosphate concentration (*i.e.* under conditions strongly favouring transcellular phosphate absorption). Consistent with the functional studies, NaPi2b protein but not *Slc34a2* mRNA, was increased in the jejunum of wild-type mice in response to calcitriol. These results strongly support NaPi2b mediated apical phosphate uptake being the only transcellular pathway responsible for increasing small intestinal phosphate absorption in response to calcitriol administration.

The authors also interrogated the effect of calcitriol on the paracellular pathway. They did so by examining phosphate flux across jejunal and ileal segments *ex vivo* in Ussing chambers in the presence of large phosphate concentration gradients (70 mM, *i.e.* conditions strongly favouring paracellular diffusive flux). They did not observe a difference in paracellular phosphate absorption in either genotype in response to calcitriol. Although, interestingly, the *Slc34a2* KO mice displayed reduced paracellular phosphate flux across the ileum by this method. To confirm that calcitriol had no effect on the paracellular pathway they determined paracellular phosphate permeability of the jejunum and ileum *ex vivo* in Ussing chambers by measuring phosphate to chloride bionic diffusion potentials. This failed to detect a difference in phosphate permeability in either genotype, before or after treatment with calcitriol. Thus, in the small intestine at least, it appears that calcitriol does not enhance intestinal phosphate absorption by increasing paracellular phosphate absorption.

This work contributes much to our understanding of intestinal phosphate absorption but also raises some questions. Consistent with the data reported here, others have seen increased NaPi2b protein but not mRNA expression in response to calcitriol treatment, begging the question by what post-translational mechanism does this occur? Hernando et al report significant expression of *Slc30a1* and *Slc30a2* mRNA in the colon, although expression was not altered in the *Slc34a2* KO animals nor by calcitriol (4). Protein expression was not assessed. However, this raises the possibility that there could be an effect of calcitriol on colonic phosphate absorption? Further, why was less

paracellular phosphate flux observed in response to a large chemical gradient, across the ileum, but not the jejunum, of *Slc34a2* KO mice? This is particularly intriguing as phosphate permeability was not lower in the ileum of the KO mice, and both the lumen negative potential difference and concentration difference across the tissue were the same in both genotypes. Moreover, why was this difference not observed in a previous study from this group (5)? Ultimately, this work convincingly demonstrates that NaPi2b is the sole small intestinal regulator of increased phosphate absorption in response to calcitriol and that there is no effect on paracellular phosphate absorption. It also serves to highlight a central question in the field, what is the molecular identity of the paracellular phosphate pore in the intestine?

References

1. Christakos S, Dhawan P, Porta A, Mady LJ, Seth T. Vitamin D and intestinal calcium absorption. *Mol Cell Endocrinol.* 2011;347(1-2):25-9.
2. Curry JN, Saurette M, Askari M, Pei L, Filla MB, Beggs MR, et al. Claudin-2 deficiency associates with hypercalciuria in mice and human kidney stone disease. *J Clin Invest.* 2020;130(4):1948-60.
3. King AJ, Siegel M, He Y, Nie B, Wang J, Koo-McCoy S, et al. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. *Sci Transl Med.* 2018;10(456).
4. Hernando N, Pastor-Arroyo EM, Marks J, Schnitzbauer U, Knopfel T, Burki M, et al. 1,25(OH)₂ vitamin D₃ stimulates active phosphate transport but not paracellular phosphate absorption in mouse intestine. *J Physiol.* 2020.
5. Knopfel T, Himmerkus N, Gunzel D, Bleich M, Hernando N, Wagner CA. Paracellular transport of phosphate along the intestine. *Am J Physiol Gastrointest Liver Physiol.* 2019;317(2):G233-G41.

Competing Interests

Dr. Alexander has no competing interests to declare

Funding

Research in the Alexander laboratory is funded by grants from the Women and Children's Health Research Institute, which is supported by the Stollery Children's Hospital Foundation, the Canadian Institutes of Health Research, the Kidney Foundation of Canada and the National Sciences and Engineering Research Council of Canada. Dr. Alexander is a Stollery Science laboratory Distinguished Researcher and the Canada Research Chair in Renal Epithelial Transport Physiology.